Who owns DNTH? 13F holders and whale ownership
DNTH is tracked across public portfolios in Whale Analyzer. This page answers who owns DNTH, which top funds are buying DNTH, aggregate disclosed value, and recent position changes based on public data. Peter Kolchinsky is the largest reported holder at $219M; the top five funds control 100.0% of reported ownership; institutions were net buying last quarter (2 increased, 0 reduced); the stock trades above the aggregate whale cost basis of $8.3. Top tracked holders include Peter Kolchinsky and Baker Bros. Advisors.
Continue to the live DNTH dashboardTop holders
| Investor | Reported value | Shares | Change |
|---|---|---|---|
| Peter Kolchinsky 13F portfolio RA Capital Management holdings | $219.2M | 2.6M | Increased |
| Baker Bros. Advisors 13F portfolio Baker Bros. Advisors holdings | $71.5M | 852.2K | Increased |
Ownership concentration
Reported ownership of DNTH is highly concentrated across tracked institutions.
- Single largest holder: 75.4% of reported ownership
- Top 5 holders: 100.0%
- Top 10 holders: 100.0%
Whale activity this quarter
Across 2 tracked institutions, 2 increased. Net positioning is net buying.
- Peter Kolchinsky — RA Capital Management ($219.2M) (▲ 62.0% qoq shares) · avg cost $4.99
- Baker Bros. Advisors — Baker Bros. Advisors ($71.5M) (▲ 7.9% qoq shares) · avg cost $18.42
Whale cost basis vs current price
The aggregate tracked cost basis is $8.30 versus a current price of $95.35, so DNTH trades above its cost basis (+1049.2%). Average unrealized P&L across tracked holders: 1029%.
Sector positioning — Health Care
DNTH sits within the Health Care sector alongside 221 other tracked names. Compare whale ownership across peers:
How to use this page
Values are reported public positions from tracked 13F filers and disclosures — not real-time ownership totals. Open the live DNTH dashboard for price charts and cross-investor scans, or read the SEC 13F guide.
Related stock holder pages
- ASND whale holders — ASCENDIS PHARMA A/S - ADR
- PCVX whale holders — VAXCYTE INC
- RYTM whale holders — RHYTHM PHARMACEUTICALS INC
- TYRA whale holders — TYRA BIOSCIENCES INC
- SION whale holders — SIONNA THERAPEUTICS INC
- EWTX whale holders — EDGEWISE THERAPEUTICS INC
- NAMSW whale holders — NEWAMSTERDAM PHARMA CO NV
- NUVL whale holders — NUVALENT INC-A
Learn more in Whale Analyzer Academy
Deepen your read on DNTH with these Whale Analyzer Academy guides:
Frequently asked questions
Who owns DNTH stock?
Whale Analyzer tracks 2 public institutional holders of DNTH with a combined reported value of $290.7M. See the holder table above for the largest tracked positions.
Which top funds are buying DNTH?
Tracked institutions were net buying last quarter — 2 increased. Check the "Change" column: "New" = fresh position, "Increased" = added, "Reduced" = trimmed.
How concentrated is DNTH ownership?
The top five tracked holders report 100.0% of aggregate ownership.
Is DNTH above or below the whale cost basis?
The aggregate tracked cost basis is $8.30 versus a current price of $95.35 (+1049.2%).
What does 13F ownership mean for DNTH?
Use the interactive DNTH dashboard on Whale Analyzer for real-time holder analysis, or read our 13F Alpha Signals Guide.